MedTrace Logo

The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans

NCT02281396 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-01-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of Freeze-dried Rabies Vaccine （MRC-5 Cell) in healthy humans aged from 10-60 years old, according to the traditional Essen methods (1-1-1-1-1) vaccination.

Conditions

  • Rabies
  • Healthy

Interventions

BIOLOGICAL

2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old

Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old

Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)

Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)

Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval

Sponsors & Collaborators

  • Beijing Minhai Biotechnology Co., Ltd

    collaborator INDUSTRY

  • Beijing Center for Disease Control and Prevention

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-01-31
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02281396 on ClinicalTrials.gov